Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.150 +0.640 (+9.83%)
Official Closing Price Updated: 8:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies Healthcare Conference
Via Investor Brand Network
Cybin to Present at the Jefferies Healthcare Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M
Via Investor Brand Network
Topics Derivatives
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
Via Investor Brand Network
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
Via Investor Brand Network
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
Via Investor Brand Network
Cybin to Participate at the 26th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches EMBARK OA, a Cost-Free Facilitator Training Program for Psychedelic Therapy
Via Investor Brand Network
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference
Via Investor Brand Network
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions
Via Investor Brand Network
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs
Via Investor Brand Network
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
Cybin Announces Streamlined Clinical Alignment
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
Via Investor Brand Network
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Via Investor Brand Network
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Via Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study
Via Investor Brand Network
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.